HPV Cancer Prevention Program, St. Jude Children's Research Hospital, Memphis, TN, USA.
Department of Internal Medicine, School of Medicine, University of New Mexico, Albuquerque, NM, USA.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2180250. doi: 10.1080/21645515.2023.2180250. Epub 2023 Feb 20.
Human papillomavirus (HPV) vaccination is routinely recommended for adolescents aged 11 or 12 years but can begin at age 9. On-time HPV vaccination by the thirteenth birthday has proven to be effective in preventing HPV cancer and pre-cancer. However, HPV coverage rates continue to lag behind other routinely recommended vaccinations for adolescents. A promising approach to improving coverage is to start HPV vaccination at age 9. This approach has been endorsed by the American Academy of Pediatrics and the American Cancer Society. Benefits of this approach include increased time to complete vaccination series by the thirteenth birthday, additional spacing of recommended vaccines, and a more concentrated focus on cancer prevention messaging. While promising, little is known about how and if existing evidence-based interventions and approaches can be used to promote starting HPV vaccination at age 9. Implementation science frameworks offer scientific direction in how to adapt current and develop new interventions to promote starting HPV vaccination at age 9 and accelerate dissemination and prevent HPV cancers.
人乳头瘤病毒(HPV)疫苗接种通常建议 11 或 12 岁的青少年接种,但也可以从 9 岁开始。在 13 岁生日前及时接种 HPV 疫苗已被证明能有效预防 HPV 癌症和癌前病变。然而,HPV 疫苗的接种率仍然落后于其他为青少年推荐的常规疫苗。提高接种率的一个有希望的方法是从 9 岁开始接种 HPV 疫苗。这一方法得到了美国儿科学会和美国癌症协会的认可。这种方法的好处包括增加了在 13 岁生日前完成疫苗系列接种的时间,增加了推荐疫苗的间隔时间,以及更集中地关注癌症预防信息。尽管前景广阔,但对于如何以及是否可以利用现有的循证干预措施和方法来促进 9 岁开始接种 HPV 疫苗,我们知之甚少。实施科学框架为如何调整现有干预措施和制定新的干预措施以促进 9 岁开始接种 HPV 疫苗以及加速传播和预防 HPV 癌症提供了科学指导。